May 25, 2021 7:43am
News: Pluristem (PSTI +$0.20 pre-market) announced the receipt of a “Disbursement Offer” in the amount of US$24 million from the European Investment Bank (EIB).
Pre-open indications: 2 BUY and 1 Maintain SELL
Mentions: PSTI, BLUE, BSTG
My version of the morning’s “indications” is written on what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are UP +0.26% (+90 points), S&P futures are UP +0.32% (+13 points) and NASDAQ futures are UP +0.53% (+72 points)
U.S. stock futures were slightly higher pre-open on Tuesday,
European stocks advanced lifting global market sentiment,
Asia-Pacific stocks rose with mainland Chinese markets leading the way.
Henry’omics:
Yesterday, Monday, the Dow was up, the S&P 500 climbed and the Nasdaq jumping 1.4% as the small-cap benchmark Russell 2000 climbed 0.5%.
I tend to think the sector will be defensive today, hoping to hold-on to the ups and minimizing some downs.
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (31) to date … https://www.regmedinvestors.com/articles/11628
Monday’s evening’s recap: “interest or the lack thereof in the cell and gene therapy sector” … https://www.regmedinvestors.com/articles/11925
- The Nasdaq closed UP +190.18 points (+1.41%);
- The IBB closed down -0.61% and XBI closed down -0.66%
- Sector volume was LOW with 2 of the 9-upside having higher than the 3-month average volume with the volume of 2 of 23-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -1.75 points or -8.68% at 18.40
- Monday’s percentage (%) of the 9-upside were +0.03% (CRSP) to +24.76% (VSTM) while the 23-downside ranges from -0.06% (EDIT) to -4.69% (AGTC);
Q2/21
May: 4 positive and 11 negative closes
April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Biostage (BSTG): Questions continue … Maintaining Sell
Biostage (BSTG) closed flat at $1.30 with 45 shares traded after Friday’s +$0.02 to $1.32 with 299 shares traded, Thursday at $1.30 with 1 share traded, Wednesday’s +$0.16 to $1.30 with 930 shares traded and last Tuesday’s -$0.16 to $1.13 with 250 shares traded.
Question#1: After earnings’ release, WHAT is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance? With only $500 K in the “till” and a two (2) month runway with a $900 K “spend”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).
Question#2: Has Hong Yu’s tenure as president brought about ANY change to BSTG’s “condition” of going NOWHERE?
MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications: I am “hanging-back” this a.m. re forecasting indications – there is an anxiety snaking through the sector.
BUY:
Pluristem (PSTI) closed down -$0.11 to $3.80 and has a positive +$0.20 or +5.26% on news of the receipt of a “Disbursement Offer” in the amount of €20 million (approximately $24 million) from the European Investment Bank (EIB). This disbursement – the first of three tranches of funding – reflects that PSTI has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement. Pursuant to the EIB agreement, PSTI expects to receive the first tranche of funds during June 2021.
BUY from SELL:
bluebird bio (BLUE) closed down -$0.95 to $30.60 after Friday’s +$0.83 to $31.55, Thursday’s +$1.29 to $30.72, Wednesday’s -$1.24 to $29.43, Tuesday’s +$0.76 to $30.67 and last Monday’s -$0.41 to $29.91 with a negative -$0.15 or +0.48% pre-market indications.
The BOTTOM LINE: I feel like a song from a broken record, “post earnings’ release, BUY some (few) short-term dips but, cautiously”.
My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
